Clinical trial
Randomized Phase III Study of the Addition of Cisplatin in Combination With Gemcitabine as First-line Therapy for Elderly Patients With Advanced Non Small Cell Lung Cancer.
NCT01405586 is registered in ClinicalTrials.gov with National Cancer Institute, Naples as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized Phase III Study of the Addition of Cisplatin in Combination With Gemcitabine as First-line Therapy for Elderly Patients With Advanced Non Small Cell Lung Cancer.
- Lead sponsor
- National Cancer Institute, Naples
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- March 31, 2011
- Completion date
- November 30, 2024
- Enrollment
- 299 (actual)
- Sites
- 49
Conditions
As the registry lists them; a condition with its own page is linked.
non-small cell lung cancer metastatic, non-small cell lung cancer stage iiib